Phase IIII trial with fozivudine tidoxil (BM 21.1290): A 7 day randomized, placebo-controlled dose-escalating trial

Antiviral Therapy

Volumn 2, Issue 4, 1997, Pages 257-264

  Bogner, J R ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FOZIVUDINE TIDOXIL; PLACEBO; UNCLASSIFIED DRUG; ZIDOVUDINE DERIVATIVE; ZIDOVUDINE GLUCURONIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; LIPID; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; IMMUNOLOGY; MIDDLE AGED; VIROLOGY;

ADULT; ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; LIPIDS; MALE; MIDDLE AGED; RNA, VIRAL; ZIDOVUDINE;

EID: 0031282842     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Gazzard BG, Moyle GJ, Weber J, Johnson M, Bingham JS Brettle R, Churchill D, Fisher M, Griffin G, Jefferies D, King E, Gormer R, Lee C, Pozniak A, Smith JR, Tudor-Williams G & Williams J. British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349:1086-1092.
2. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG & Volberding PA. Antiretroviral therapy for HIV infection in 1997. Recommendations of an international panel. International AIDS Society-USA. Journal of the American Medical Association 1997; 277:1962-1969.
3. Herrmann DBJ, Kucera LS, Zilch H, Mertens A & Opitz HG. BM21.1290: In vitro evaluation of a potential new anti-AIDS compound. XI International Conference on AIDS, Vancouver Canada 1996; Abstract MoA 1057.
4. Herrmann DBJ, Schleger C & Opitz HG. Antiretroviral activity of the novel candidate anti-AIDS drug BM 21.1290 in the Friend leukaemia system in vivo. 6 Deutscher AIDS- Kongress, InfFo 1994;B96:Abstract V160.
5. Herrmann DBJ & Opitz HG. BM 21.1290: Pharmacological/toxicological evaluation of a novel candidate anti AIDS drug. AIDS 1996; 10 Supplement 2:S39 (Abstract).